Allarity shares rise 10.47% intraday after VA-funded Phase 2 trial of stenoparib and temozolomide in relapsed SCLC begins.

Allarity Therapeutics (ALLR) surged 10.47% intraday following the announcement that it dosed its first patients in a VA-funded Phase 2 trial evaluating stenoparib combined with temozolomide for relapsed small cell lung cancer (SCLC). The trial, conducted at 11 VA sites and fully funded by the U.S. Department of Veterans Affairs, targets a high-unmet-need oncology segment where existing treatments are limited by toxicity and short duration. Stenoparib’s dual PARP/WNT inhibition mechanism is highlighted as a potential improvement over first-generation PARP inhibitors, with the CEO noting its favorable safety profile and rapid enrollment. The trial’s focus on SCLC, a lethal cancer with limited second-line options, and the drug’s ability to cross the blood-brain barrier further underscore its clinical relevance. The VA’s involvement and the trial’s alignment with unmet medical needs likely drove the sharp intraday price increase.